Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | DRD1 | P21728 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.76 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpromazine SCHEMBL18993 | 1.00 | CHRM2 (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL18994 | 1.00 | CHRM2 (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL2774391 | 0.98 | CHRM2 (0.97) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL6944155 | 0.89 | HTR1A (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL2615384 | 0.89 | HTR1A (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL719590 | 0.88 | GFER (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Ethopropazine SCHEMBL3690174 | 0.88 | HSD17B10 (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL409663 | 0.88 | GFER (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL21293802 | 0.88 | GFER (0.82) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL13284571 | 0.88 | CHRM2 (0.78) | CHRM2HTR1AADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028676-A1 | METHODS FOR SELECTING MEDICATIONS FOR TREATING PATIENTS HAVING ATTENTION-DEFICIT HYPERACTIVITY DISORDER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| EP-3801531-B1 | LOW GLYCEMIC GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-09-18 | — | — | EP | claimed |
| US-20240173277-A1 | ANTI-MYCOBACTERIAL DRUGS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-05-30 | — | — | US | claimed |
| US-11974972-B1 | Anti-mycobacterial drugs | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-05-07 | — | — | US | claimed |
| US-20240122681-A1 | Dental / Prosthetic Implant | TOSCANO ELISANDRO R (US) | 2024-04-18 | — | — | US | claimed |
| EP-3641774-B1 | PECTIN GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-03-27 | — | — | EP | claimed |
| US-20240000732-A1 | ANTI-MYCOBACTERIAL DRUGS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-01-04 | — | — | US | claimed |
| US-11857521-B1 | Anti-mycobacterial drugs | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-01-02 | — | — | US | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| CN-114072132-A | Bionic tissue adhesive hydrogel patch and application thereof | 赛拉尔研究有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026105151-A1 | IMPROVED IN-SITU SYNTHESIS OF AMINO METHYL PROPANOIC ACID | OPTICELLAR INNOVATION PRIVATE LIMITED (IN) | 2026-05-21 | — | — | WO | disclosed |
| US-20220040226-A1 | SYNERGISTIC MEDICINAL COMPOSITIONS FOR TREATING DYSFUNCTIONAL D-SERINE SIGNALING | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-02-10 | — | — | US | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11229626-B2 | Synergistic nutritional compositions for treating seizures and chronic inflammatory diseases | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | HRH1 3652/4885CHRM2 1115/4885HTR1A 1697/4885 |
| US-20240173277-A1 | ANTI-MYCOBACTERIAL DRUGS | OAT, OGA, OTC | HRH1 3551/4885CHRM2 1983/4885HTR1A 4466/4885 |
| US-20260028676-A1 | METHODS FOR SELECTING MEDICATIONS FOR TREATING PATIENTS HAVING ATTENTION-DEFICIT HYPERACTIVITY DISORDER | SLC6A3, SLC6A2, SLC6A4 | HRH1 3076/4885CHRM2 597/4885HTR1A 69/4885 |
| US-11974972-B1 | Anti-mycobacterial drugs | OAT, OGA, OTC | HRH1 3551/4885CHRM2 1983/4885HTR1A 4466/4885 |
| US-20220040226-A1 | SYNERGISTIC MEDICINAL COMPOSITIONS FOR TREATING DYSFUNCTIONAL D-SERINE SIGNALING | DDO, SRR, DAO | HRH1 2759/4885CHRM2 693/4885HTR1A 734/4885 |
| US-11229626-B2 | Synergistic nutritional compositions for treating seizures and chronic inflammatory diseases | GRIK2, GRIK5, GRIK1 | HRH1 1867/4885CHRM2 958/4885HTR1A 3073/4885 |
| US-11857521-B1 | Anti-mycobacterial drugs | OAT, OGA, OTC | HRH1 3551/4885CHRM2 1983/4885HTR1A 4466/4885 |
| US-20240000732-A1 | ANTI-MYCOBACTERIAL DRUGS | OAT, OGA, OTC | HRH1 3551/4885CHRM2 1983/4885HTR1A 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.